Entresto (sacubitril/valsartan): new heart failure combination tablet 'could replace ACE inhibitors as mainstay of treatment'
A combination of valsartan and the new drug sacubitril is the first treatment to show a significant mortality benefit over enalapril in patients with heart failure. The combined tablet, Entresto, is now available to prescribe.
by Moriam Adetokunboh-Ajala
To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.